TECNIS PureSee IOL

TECNIS PureSee IOL clinical data took center stage at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, as Johnson & Johnson Vision presented compelling new evidence regarding its latest intraocular lens. The data highlights a significant leap forward in refractive technology, offering patients a purely refractive, non-diffractive design that delivers a continuous range of vision. TECNIS PureSee IOL Delivers Unmatched Contrast Sensitivity One of the primary concerns for patients undergoing cataract surgery is the potential loss of contrast sensitivity often associated with multifocal lenses. However, the latest study on the TECNIS PureSee IOL demonstrates that this lens provides a contrast sensitivity profile comparable to a monofocal lens. This ensures that patients can enjoy high-quality vision even in low-light conditions, such as driving at night or reading in a dimly lit room. The presentation at ASCRS 2026 revealed that the TECNIS PureSee IOL maintains excellent image quality across all lighting environments. By utilizing a unique purely refractive design, the lens avoids the "rings" often found in diffractive IOLs, which can cause glare and halos. Read More: Johnson & Johnson Announces $2 Billion Investment in North Carolina Manufacturing Facility Extending the Range of Vision with TECNIS PureSee IOL Technology The core benefit of the TECNIS PureSee IOL is its ability to provide an extended range of vision. Unlike traditional lenses that focus solely on distance, this innovative technology allows for high-quality distance and intermediate vision, with functional near vision. This reduces the dependency on glasses for daily tasks like using a smartphone or working on a computer. Patient Satisfaction and Clinical Reliability During the ASCRS sessions, lead investigators shared that patients implanted with the TECNIS PureSee IOL reported high levels of satisfaction. The "easy-to-fit" nature of the lens also makes it a preferred choice for surgeons, as it is more forgiving regarding slight misalignments compared to complex diffractive designs. The TECNIS PureSee IOL represents a shift in how we approach presbyopia-correcting surgery, We are providing the range of vision patients desire without the visual trade-offs they fear. Spokesperson for Johnson & Johnson Clinical Outcomes: TECNIS PureSee IOL Performance The following data is compiled from a real-world, post-market observation study (N293) and a U.S. prospective, randomized clinical trial (N200) featured at the 2026 conference. MetricClinical Result (Mean/Percentage)Notes vs. Monofocal ControlBinocular Uncorrected Distance (UVA)20/19Comparable to monofocalBinocular Best-Corrected Distance20/18Equivalent high-quality distanceIntermediate Visual Acuity (UIVA)20/26 to 20/28Significantly improved vs. controlNear Visual Acuity Improvement+1.5 lines (gain)Greater functional near visionContrast Sensitivity≤ 0.3 log units differenceComparable to aspheric monofocalSpectacle Independence (Distance)96%High independenceSpectacle Independence (Intermediate)95%Excellent for computer/dashboardsSpectacle Independence (Near)61%Functional; may need light reading aidsNo "Very Bothersome" Halo93%Monofocal-like disturbance profileNo "Very Bothersome" Glare91%Highly refractive, non-diffractiveOverall Patient Satisfaction97%97% would recommend to others Company: Johnson & Johnson